Yoash Zohar - Evogene Chief Ltd
| EVGN Stock | USD 1.67 0.05 3.09% |
Executive
Yoash Zohar is Chief Ltd of Evogene
| Age | 57 |
| Address | 13 Gad Feinstein Street, Rehovot, Israel, 7638517 |
| Phone | 972 8 931 1900 |
| Web | https://www.evogene.com |
Evogene Management Efficiency
The company has return on total asset (ROA) of (0.2846) % which means that it has lost $0.2846 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.8237) %, meaning that it created substantial loss on money invested by shareholders. Evogene's management efficiency ratios could be used to measure how well Evogene manages its routine affairs as well as how well it operates its assets and liabilities. As of the 26th of November 2024, Return On Tangible Assets is likely to drop to -0.66. In addition to that, Return On Capital Employed is likely to drop to -0.63. At this time, Evogene's Total Assets are very stable compared to the past year. As of the 26th of November 2024, Non Currrent Assets Other is likely to grow to about 28.4 K, while Other Assets are likely to drop 0.95.Similar Executives
| Showing other executives | EXECUTIVE Age | ||
| Matthew Henn | Seres Therapeutics | 49 | |
| Emily Pimblett | Eliem Therapeutics | 40 | |
| JD Esq | Seres Therapeutics | 69 | |
| Valerie Morisset | Eliem Therapeutics | 54 | |
| John PharmD | Scpharmaceuticals | N/A | |
| Carlo Tanzi | Seres Therapeutics | N/A | |
| Caroline Holda | Seres Therapeutics | N/A | |
| Lisa MD | Seres Therapeutics | 65 | |
| RPh Young | Seres Therapeutics | 57 | |
| Lee Flowers | HCW Biologics | 78 | |
| SPHR SHRMSCP | Seres Therapeutics | 52 | |
| Kim Fox | Milestone Pharmaceuticals | N/A | |
| David Ege | Seres Therapeutics | 49 | |
| Nishi MD | Eliem Therapeutics | N/A | |
| Nicole Esq | HCW Biologics | N/A | |
| Roshan Girglani | Milestone Pharmaceuticals | N/A | |
| Alpa Parikh | Lumos Pharma | N/A | |
| Rachael Nokes | Scpharmaceuticals | 49 | |
| MD FAAP | Lumos Pharma | N/A | |
| MD MBA | Eliem Therapeutics | 50 | |
| Steve Parsons | Scpharmaceuticals | N/A | |
Management Performance
| Return On Equity | -0.82 | ||||
| Return On Asset | -0.28 |
Evogene Leadership Team
Elected by the shareholders, the Evogene's board of directors comprises two types of representatives: Evogene inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Evogene. The board's role is to monitor Evogene's management team and ensure that shareholders' interests are well served. Evogene's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Evogene's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Mark Kapel, Executive Vice President-Technology | ||
| Rachel Gerber, Head Relations | ||
| Amit res, Chief Ltd | ||
| Dotan Borenstein, Chief Ltd | ||
| Yaron Eldad, Chief Officer | ||
| Eyal Ronen, Executive Development | ||
| Nir Arbel, Chief Officer | ||
| Eyal Emmanuel, Executive Vice President-R&D | ||
| Sassi Masliah, Vice Development | ||
| Brian Ember, Chief Ltd | ||
| Liat Wejgman, Vice Resources | ||
| Yoash Zohar, Chief Ltd | ||
| Ofer CPA, CEO President | ||
| Elran MBA, Chief Ltd |
Evogene Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Evogene a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.82 | ||||
| Return On Asset | -0.28 | ||||
| Profit Margin | (2.10) % | ||||
| Operating Margin | (6.67) % | ||||
| Current Valuation | (322.05 K) | ||||
| Shares Outstanding | 5.37 M | ||||
| Shares Owned By Insiders | 1.66 % | ||||
| Shares Owned By Institutions | 11.10 % | ||||
| Number Of Shares Shorted | 22.35 K | ||||
| Price To Earning | (5.22) X |
Pair Trading with Evogene
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Evogene position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Evogene will appreciate offsetting losses from the drop in the long position's value.Moving together with Evogene Stock
| 0.82 | ME | 23Andme Holding | PairCorr |
| 0.89 | VALN | Valneva SE ADR | PairCorr |
| 0.77 | JNJ | Johnson Johnson Fiscal Year End 28th of January 2025 | PairCorr |
Moving against Evogene Stock
| 0.63 | MDGL | Madrigal Pharmaceuticals | PairCorr |
| 0.5 | RNXT | RenovoRx | PairCorr |
| 0.45 | NXGLW | NexGel Warrant | PairCorr |
| 0.4 | KZR | Kezar Life Sciences | PairCorr |
| 0.35 | MLYS | Mineralys Therapeutics, | PairCorr |
The ability to find closely correlated positions to Evogene could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Evogene when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Evogene - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Evogene to buy it.
The correlation of Evogene is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Evogene moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Evogene moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Evogene can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Evogene. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in price. To learn how to invest in Evogene Stock, please use our How to Invest in Evogene guide.You can also try the Fundamentals Comparison module to compare fundamentals across multiple equities to find investing opportunities.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Evogene. If investors know Evogene will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Evogene listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (4.46) | Revenue Per Share 1.881 | Quarterly Revenue Growth 0.398 | Return On Assets (0.28) | Return On Equity (0.82) |
The market value of Evogene is measured differently than its book value, which is the value of Evogene that is recorded on the company's balance sheet. Investors also form their own opinion of Evogene's value that differs from its market value or its book value, called intrinsic value, which is Evogene's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Evogene's market value can be influenced by many factors that don't directly affect Evogene's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Evogene's value and its price as these two are different measures arrived at by different means. Investors typically determine if Evogene is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Evogene's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.